

338 - 346

7 Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study [J]. *Ophthalmology*, 2005, 112: 1035 - 1047

8 Nguyen QD, Shas S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia [J]. *Br J Ophthalmol*, 2005, 89: 1368 - 1370

9 Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. *N Engl J Med*, 2004, 350(23): 2335 - 2342

10 Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration [J]. *Ophthalmol Surg Laser Imaging*, 2005, 36(4): 331 - 335

11 Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration [J]. *Retina*, 2006, 26: 495 - 511

12 Yamamoto I, Roger AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia [J]. *Br J Ophthalmol*, 2007, 91: 157 - 160

13 Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide [J]. *Br J Ophthalmol*, 2006, 90(11): 1344 - 1349

14 Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration [J]. *Graefe's Arch Clin Exp Ophthalmol*, 2007, 245(1): 68 - 73

15 Chan WM, Lai TYY, Liu DTL, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctuate inner choroidopathy, or of idiopathic origin [J]. *Am J Ophthalmol*, 2007, 143: 977 - 983

16 Gomi F, Nishida K, Oshima Y, et al. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone [J]. *Am J Ophthalmol*, 2007, 143: 507 - 509

(收稿:2008-07-25 修回:2009-04-17)

(本文编辑:高红)

· 病例报告 ·

年龄相关性特发性黄斑裂孔自愈一例

罗光伟 郑小平

患者,女,70岁。于2006年10月8日因右眼视力下降3个月就诊。眼科检查:视力右眼0.1,左眼1.0,双眼外眼未见异常,角膜透明,晶状体皮质轻度混浊,右眼黄斑区疑似全层裂孔,视网膜其他部位未见异常。左眼眼底正常。光学相干断层扫描仪(OCT)检查,右眼黄斑中心凹有囊样变性,中央部较大的囊腔顶有一小裂孔,直径155 μm,孔底直径758 μm,玻璃体不完全性后脱离(图1)。临床诊断:右眼年龄相关性特发性黄斑裂孔。患者未同意行玻璃体切割裂孔封闭手术,故门诊观察。于2008年12月15日再次来诊,视力右眼0.5,左眼1.0,右眼黄斑区裂孔封闭,黄斑中心凹平伏,余同术前。OCT检查黄斑中心凹裂孔封闭,留有视网膜色素上皮局限性断裂,玻璃体后脱离表现同前(图2)。




图1 初诊时黄斑裂孔 OCT 图像 图2 复诊时黄斑裂孔愈合后 OCT 图像

讨论:1988年Gass首先提出了年龄相关性特发性黄斑裂孔的临床分期和发生机制,认为裂孔的发生与玻璃体牵引有关。随着OCT等眼底形态学测量仪器的出现,Gass的这一学说得以证实。OCT分辨率高达10 μm,可以直观准确地显示裂孔的形态、大小及有无合并周围视网膜脱离等各种情况,同时也可以观察视网膜受玻璃体牵拉的程度及二者之间的关系,为

黄斑裂孔的临床分期、手术方案的制定及随访观察提供了可靠的依据^[1]。

黄斑裂孔一旦形成则极少自愈,一般会进一步扩大^[2],有关特发性黄斑裂孔自愈的报道较少。李永等^[3]报道了3例黄斑裂孔自愈的患者,其中1例为特发性裂孔。外伤性黄斑裂孔的自愈率要高于特发性裂孔。李学伟等^[4]报道了28例外伤性黄斑裂孔的随访研究,发现在裂孔形成后1~4个月,有10.7%的裂孔自行闭合。Privat等^[5]报道了510例特发性黄斑裂孔患者,其中有14例患者的裂孔发生自愈,发生率为2.7%,均是裂孔直径较小(一般<400 μm)的患者。根据Gass分期,本例患者初诊时为Ⅱ期裂孔,应属于小孔径裂孔。因此,当造成玻璃体牵拉的原因自行解除后,小孔径黄斑裂孔有自愈的可能。

参考文献

1 魏雁涛,张磊,孙慧敏,等. 光学相干断层扫描对自发性黄斑裂孔成因的探讨 [J]. *中国实用眼科杂志*, 2002, 20(8): 580 - 581

2 Win PH, Young TA. Spontaneous macular hole closure in bilateral macular holes [J]. *Semin Ophthalmol*, 2007, 22(3): 167 - 169

3 李永,戴虹,夏群,等. 应用OCT观察黄斑裂孔的自发闭合 [J]. *中国实用眼科杂志*, 2003, 2(5): 399 - 400

4 李学伟,卢宁,张兰,等. 外伤性黄斑裂孔的随访观察 [J]. *中华眼科杂志*, 2008, 44(9): 786 - 789

5 Privat E, Tadayoni R, Gaucher D, et al. Residual defect in the foveal photoreceptor layer detected by optical coherence tomography in eyes with spontaneously closed macular holes [J]. *Am J Ophthalmol*, 2007, 143(5): 814 - 819